BSX Set to Release Q1 Earnings with Strong Estimates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy BSX?
Source: Newsfilter
- Earnings Expectations: BSX is set to release its Q1 earnings on April 22, with an estimated EPS of $0.79 and revenue projected at $5.17 billion, indicating stable performance in the market despite some pressures.
- Stock Price Movement: On Tuesday, BSX's stock fell by 2.4%, reflecting a cautious market sentiment ahead of the earnings report, which could impact investor confidence and requires monitoring of subsequent stock performance.
- Analyst Ratings: The majority of analysts rate BSX as a 'Buy', suggesting strong market confidence in the company's growth potential, which may attract more investor interest in its shares.
- Market Context: In the current economic environment, BSX's robust earnings expectations combined with positive analyst ratings could provide the company with a competitive edge in the fiercely contested medical device industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 60.990
Low
94.00
Averages
108.14
High
132.00
Current: 60.990
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Set to Announce Q1 Earnings on April 22
- Earnings Announcement: Boston Scientific (BSX) is set to release its Q1 2023 earnings report on April 22 before market open, with consensus EPS estimated at $0.79, reflecting a 5.3% year-over-year increase, and revenue expected to reach $5.17 billion, up 10.9% year-over-year, indicating strong growth potential.
- Historical Performance: Over the past two years, BSX has consistently beaten EPS and revenue estimates 100% of the time, showcasing the company's financial stability and market confidence, which could further enhance investor sentiment.
- Estimate Revision Trends: In the last three months, BSX's EPS estimates have seen 7 upward revisions and 10 downward revisions, while revenue estimates have experienced 7 upward and 8 downward revisions, reflecting mixed market perceptions about the company's future performance that may influence investor decisions.
- Sector Performance Insight: In Q1 2023, Boston Scientific is identified as one of the most oversold large-cap stocks in the U.S., and despite the healthcare sector lagging, BSX's potential for growth continues to attract investor interest.
See More
BSX Set to Release Q1 Earnings with Strong Estimates
- Earnings Expectations: BSX is set to release its Q1 earnings on April 22, with an estimated EPS of $0.79 and revenue projected at $5.17 billion, indicating stable performance in the market despite some pressures.
- Stock Price Movement: On Tuesday, BSX's stock fell by 2.4%, reflecting a cautious market sentiment ahead of the earnings report, which could impact investor confidence and requires monitoring of subsequent stock performance.
- Analyst Ratings: The majority of analysts rate BSX as a 'Buy', suggesting strong market confidence in the company's growth potential, which may attract more investor interest in its shares.
- Market Context: In the current economic environment, BSX's robust earnings expectations combined with positive analyst ratings could provide the company with a competitive edge in the fiercely contested medical device industry.
See More
Market Volatility and Corporate Earnings Updates
- Oil Price Surge Impact: The U.S. WTI crude oil price jumped 5% to $94 per barrel, causing the benchmark 10-Year Treasury yield to rise to 4.3%, leading to a market pullback after early gains, indicating investor sensitivity to oil price fluctuations.
- Mixed Earnings Reactions: While many companies exceeded analyst EPS expectations, such as UnitedHealth beating by 66 cents, most only slightly raised their full-year outlooks, reflecting management's cautious stance amid economic uncertainty.
- Ongoing Geopolitical Effects: Vice President JD Vance's diplomatic trip was postponed due to Iran's lack of response to U.S. negotiating positions, and despite a calming of geopolitical tensions, the market remains uneasy about the future of the Iran war ceasefire, impacting investor confidence.
- Upcoming Earnings Focus: Capital One is expected to report total revenue of $15.36 billion and adjusted EPS of $4.55, with investors looking for more meaningful synergies from the Discover acquisition, highlighting concerns about future growth prospects.
See More
Multiple Companies Face Class Action Lawsuits
- Lakeland Industries Lawsuit: Lakeland Industries is facing allegations for the period from December 2023 to December 2025, claiming they failed to disclose significant issues with their Pacific Helmets and Jolly businesses, including production delays and slow product rollouts, which misled investors about the company's financial health.
- Franklin BSP Realty Lawsuit: Franklin BSP Realty Trust is accused of overstating its ability to maintain a $0.355 dividend during the class period from November 2024 to February 2026, which has negatively impacted investor confidence in the company's future prospects.
- Apollo Global Lawsuit: Apollo Global Management is under scrutiny for undisclosed communications between executives and Jeffrey Epstein from May 2021 to February 2026, which has harmed the company's reputation and rendered its positive statements about business prospects misleading.
- Boston Scientific Lawsuit: Boston Scientific is facing allegations for the period from July 2025 to February 2026, claiming they did not disclose the unsustainable growth of their U.S. electrophysiology segment, misleading investors regarding the company's growth potential.
See More
Class Action Lawsuits Filed Against Boston Scientific and Others
- Boston Scientific Lawsuit: A class action lawsuit against Boston Scientific Corporation (NYSE:BSX) alleges that from July 23, 2025, to February 3, 2026, the company failed to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, which severely undermined investor confidence and is expected to negatively impact stock performance.
- Eos Energy Issues: Eos Energy Enterprises (NASDAQ:EOSE) faces a class action lawsuit for the period from November 5, 2025, to February 26, 2026, alleging that the company could not achieve necessary production ramp-up and that its battery line downtime exceeded industry norms, potentially leading to a decline in market share and investor trust.
- Soleno Therapeutics Risks: Soleno Therapeutics, Inc. (NASDAQ:SLNO) is accused in a class action lawsuit covering March 26, 2025, to November 4, 2025, of concealing significant safety concerns related to its DCCR clinical trial, which could materially affect its commercial viability and expose investors to legal and reputational risks.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics (NASDAQ:NKTR) is implicated in a class action lawsuit for the period from February 26, 2025, to December 15, 2025, for failing to adhere to trial protocols in its REZOLVE-AA trial, likely compromising the trial's integrity and further eroding investor confidence in the company's future prospects.
See More
Faruqi & Faruqi Encourages Boston Scientific Investors to Contact for Legal Options
- Legal Action Reminder: Faruq & Faruqi, LLP is investigating potential claims against Boston Scientific Corporation, specifically targeting investors who purchased or acquired the company's securities between July 23, 2025, and February 3, 2026, highlighting the legal risks they may face.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly, providing the phone numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss their legal rights and options.
- Class Action Deadline: Investors should be aware that the deadline to seek the role of lead plaintiff in the federal securities class action against Boston Scientific is May 4, 2026, making this date crucial for affected investors.
- Law Firm Background: Faruq & Faruqi, LLP is a leading national securities law firm focused on providing legal support to investors, helping them protect their rights in the securities market, especially when facing potential litigation.
See More
Boston Scientific Set to Announce Q1 Earnings on April 22
- Earnings Announcement: Boston Scientific (BSX) is set to release its Q1 2023 earnings report on April 22 before market open, with consensus EPS estimated at $0.79, reflecting a 5.3% year-over-year increase, and revenue expected to reach $5.17 billion, up 10.9% year-over-year, indicating strong growth potential.
- Historical Performance: Over the past two years, BSX has consistently beaten EPS and revenue estimates 100% of the time, showcasing the company's financial stability and market confidence, which could further enhance investor sentiment.
- Estimate Revision Trends: In the last three months, BSX's EPS estimates have seen 7 upward revisions and 10 downward revisions, while revenue estimates have experienced 7 upward and 8 downward revisions, reflecting mixed market perceptions about the company's future performance that may influence investor decisions.
- Sector Performance Insight: In Q1 2023, Boston Scientific is identified as one of the most oversold large-cap stocks in the U.S., and despite the healthcare sector lagging, BSX's potential for growth continues to attract investor interest.
See More
BSX Set to Release Q1 Earnings with Strong Estimates
- Earnings Expectations: BSX is set to release its Q1 earnings on April 22, with an estimated EPS of $0.79 and revenue projected at $5.17 billion, indicating stable performance in the market despite some pressures.
- Stock Price Movement: On Tuesday, BSX's stock fell by 2.4%, reflecting a cautious market sentiment ahead of the earnings report, which could impact investor confidence and requires monitoring of subsequent stock performance.
- Analyst Ratings: The majority of analysts rate BSX as a 'Buy', suggesting strong market confidence in the company's growth potential, which may attract more investor interest in its shares.
- Market Context: In the current economic environment, BSX's robust earnings expectations combined with positive analyst ratings could provide the company with a competitive edge in the fiercely contested medical device industry.
See More
Market Volatility and Corporate Earnings Updates
- Oil Price Surge Impact: The U.S. WTI crude oil price jumped 5% to $94 per barrel, causing the benchmark 10-Year Treasury yield to rise to 4.3%, leading to a market pullback after early gains, indicating investor sensitivity to oil price fluctuations.
- Mixed Earnings Reactions: While many companies exceeded analyst EPS expectations, such as UnitedHealth beating by 66 cents, most only slightly raised their full-year outlooks, reflecting management's cautious stance amid economic uncertainty.
- Ongoing Geopolitical Effects: Vice President JD Vance's diplomatic trip was postponed due to Iran's lack of response to U.S. negotiating positions, and despite a calming of geopolitical tensions, the market remains uneasy about the future of the Iran war ceasefire, impacting investor confidence.
- Upcoming Earnings Focus: Capital One is expected to report total revenue of $15.36 billion and adjusted EPS of $4.55, with investors looking for more meaningful synergies from the Discover acquisition, highlighting concerns about future growth prospects.
See More
Multiple Companies Face Class Action Lawsuits
- Lakeland Industries Lawsuit: Lakeland Industries is facing allegations for the period from December 2023 to December 2025, claiming they failed to disclose significant issues with their Pacific Helmets and Jolly businesses, including production delays and slow product rollouts, which misled investors about the company's financial health.
- Franklin BSP Realty Lawsuit: Franklin BSP Realty Trust is accused of overstating its ability to maintain a $0.355 dividend during the class period from November 2024 to February 2026, which has negatively impacted investor confidence in the company's future prospects.
- Apollo Global Lawsuit: Apollo Global Management is under scrutiny for undisclosed communications between executives and Jeffrey Epstein from May 2021 to February 2026, which has harmed the company's reputation and rendered its positive statements about business prospects misleading.
- Boston Scientific Lawsuit: Boston Scientific is facing allegations for the period from July 2025 to February 2026, claiming they did not disclose the unsustainable growth of their U.S. electrophysiology segment, misleading investors regarding the company's growth potential.
See More
Class Action Lawsuits Filed Against Boston Scientific and Others
- Boston Scientific Lawsuit: A class action lawsuit against Boston Scientific Corporation (NYSE:BSX) alleges that from July 23, 2025, to February 3, 2026, the company failed to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, which severely undermined investor confidence and is expected to negatively impact stock performance.
- Eos Energy Issues: Eos Energy Enterprises (NASDAQ:EOSE) faces a class action lawsuit for the period from November 5, 2025, to February 26, 2026, alleging that the company could not achieve necessary production ramp-up and that its battery line downtime exceeded industry norms, potentially leading to a decline in market share and investor trust.
- Soleno Therapeutics Risks: Soleno Therapeutics, Inc. (NASDAQ:SLNO) is accused in a class action lawsuit covering March 26, 2025, to November 4, 2025, of concealing significant safety concerns related to its DCCR clinical trial, which could materially affect its commercial viability and expose investors to legal and reputational risks.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics (NASDAQ:NKTR) is implicated in a class action lawsuit for the period from February 26, 2025, to December 15, 2025, for failing to adhere to trial protocols in its REZOLVE-AA trial, likely compromising the trial's integrity and further eroding investor confidence in the company's future prospects.
See More
Faruqi & Faruqi Encourages Boston Scientific Investors to Contact for Legal Options
- Legal Action Reminder: Faruq & Faruqi, LLP is investigating potential claims against Boston Scientific Corporation, specifically targeting investors who purchased or acquired the company's securities between July 23, 2025, and February 3, 2026, highlighting the legal risks they may face.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly, providing the phone numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss their legal rights and options.
- Class Action Deadline: Investors should be aware that the deadline to seek the role of lead plaintiff in the federal securities class action against Boston Scientific is May 4, 2026, making this date crucial for affected investors.
- Law Firm Background: Faruq & Faruqi, LLP is a leading national securities law firm focused on providing legal support to investors, helping them protect their rights in the securities market, especially when facing potential litigation.
See More
